Temozolomide in Patients With Advanced Cancer
Temozolomide (Temodar; Schering-Plough Research Institute, Kenilworth, NJ), an imidazotetrazine derivative, is a cytotoxic alkylating agent with anticancer activity in patients with recurrent and refractory high-grade glioma and metastatic melanoma.